ARA 290
also known as Cibinetide, pHBSP
Synthetic 11-amino-acid peptide derived from erythropoietin helix B. Non-erythropoietic but tissue-protective via innate repair receptor (EPO/CD131 heterodimer). Phase 2 trials demonstrate corneal nerve fiber regeneration, reduced neuropathic pain, and improved metabolic control in sarcoidosis-associated small fiber neuropathy and type 2 diabetes with painful neuropathy.
At a glance
SQ · Daily
Primary target — Innate repair receptor (EPO receptor / CD131 heterodimer).
Pathway — EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades.
Downstream effect — Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1) [liu-2014][culver-2017].
Origin — 11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties.
Feedback intact — N/A — does not interact with hematopoietic EPO receptor [liu-2014].
| Parameter | Value |
|---|---|
| Standard dose (Phase 2) | 4 mg / day [brines-2015][culver-2017]Sarcoidosis SFN and diabetic neuropathy trials. |
| Frequency | Once dailySelf-administered subcutaneously. |
| Duration | 28 days (Phase 2) [culver-2017]Corneal nerve improvements observed by day 28. |
| Evidence basis | Phase 2 RCTs [culver-2017][brines-2015]64-subject sarcoidosis trial, type 2 diabetes trial. |
| Route | Subcutaneous [brines-2015] |
| Timing | Any time of dayNo circadian dependence reported. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Phase 2 diabetes trial · secondary metabolic endpoints
| Outcome | Finding |
|---|---|
| Primary effect | Improved metabolic control (HbA1c, fasting glucose) [brines-2015]Secondary to neuropathy treatment; direct lipolytic effects not established. |
| HbA1c | Significant reduction vs placeboObserved in type 2 diabetes + neuropathy trial. |
| Fasting glucose | Improved in ARA 290 group |
| Body composition | Not directly quantifiedFat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity. |
- — Hypersensitivity to ARA 290
- — Active malignancy (theoretical EPO-axis concern; not observed in trials)
- 01Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
- 02Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
- 03Timing
Once daily, any time of day. Self-administered in Phase 2 trials. [brines-2015]
- 04Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established. [culver-2017]
- 05Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
Sources
of 59 rendered claims carry a resolvable citation.
- [brines-2015]Brines 2015 — ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
journal, 2015 - [culver-2017]Culver 2017 — Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.
journal, 2017 - [liu-2014]Liu 2014 — Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection.
journal, 2014 - [van-2014]van 2014 — ARA 290 for treatment of small fiber neuropathy in sarcoidosis.
journal, 2014